author-photo

Kim N. Chi

BC Cancer Agency
University of British Columbia
Vancouver Prostate Centre

523

Papers

20812

Citations

Citation Trend

Filter By

Papers (359) Sort By

Journal Conference Others

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical implications of genomic alterations in metastatic prostate cancer.

2021 Prostate Cancer and Prostatic Diseases
Show All
- Source
- Cite
- Save
Citations (2)
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Plasma exosome microRNA-155 expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A potential biomarker of response to systemic therapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (8)
PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)